Latest News
Unicycive Therapeutics, Inc.
- Why is Unicycive Therapeutics stock rallying today?
- FDA accepts Unicycive's resubmitted NDA for oxylanthanum carbonate; PDUFA 25 March 2027
- Unicycive Therapeutics Shares Rise After FDA Accepts Resubmitted NDA
- Unicycive stock jumps as FDA accepts OLC drug resubmission
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Unicycive Therapeutics, Inc. to Contact Law Firm
- Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
- Unicycive's drug was rejected twice by regulators, but CEO hopes third time is the charm
- Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
- Unicycive resubmits NDA for kidney disease drug with new vendor
- Unicycive Therapeutics faces securities class action lawsuit over public statements
- Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt
Headlines from the last 30 days, linking to the original publishers. See all market news →